CPHI China opens for international partnering after China rises in CPHI Index
Retrieved on:
Monday, June 6, 2022
Online, Life, Abbreviated New Drug Application, Association, FDF, Health, Pennsylvania Convention Center, Research, Exhibition, Fashion, IMPACT, Bioproduction, Food, Health care, MAH, Ministry of Health, Nutrition and Indigenous Medicine, API, Growth, Real estate, Medication, Murina, ICSE, National Capital Region (India), Paris Expo Porte de Versailles, Online and offline, Construction, Fine chemical, Video game, Messe Frankfurt
SHANGHAI, June 6, 2022 /PRNewswire/ -- CPHI & P-MEC China opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country report strong underlying conditions and see increases in all categories of the most recent CPHI Pharma Index[1] – an annual score of each country's pharma industry strength – with its overall score rising by 7.2%, the largest increase of any nation.
Key Points:
- The two-month digital partnering platform takes on increased importance with the postponement of the in-person exhibition until December (20th-22nd) 2022.
- High quality partners are in great demand and we wanted to simplify process of nurturing new contacts," commentedLaura Murina, Brand Manager at CPHI & P-MEC China.
- China recorded the largest year-on-year gains in the CPHI Pharma Index[2] for 'solid dose manufacturing innovation', 'quality of bioprocessing' and 'API manufacturing' with rises of 9.5%, 11% and 7.4% respectively and international companies should anticipate the need to source partners much earlier as demand rises.
- CPHI & P-MEC China is encouraging all international attendees to utilise its Hosted Buyer Programme.